Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-509

Spoiler Alert! The Greenfund tells you it is good.

I do not agree with some of this article - especially suggestions of BOT management shortcomings as for example the very notion of double-blind is IMO suggestive of a certain lack of control of events - but please read in its entirety and absorb the last two paragraphs:

"Our view and investing thesis has not changed. The drug is efficacious and safe and is targeting a significant addressable market. We are still firmly behind the management team and company and believe the current share price offers an unbelievably attractive opportunity for investors looking to initiate a position, or to dollar average down their existing position.

And this is exactly what we did yesterday."